1618P Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)
2023; Elsevier BV; Volume: 34; Linguagem: Inglês
10.1016/j.annonc.2023.09.2567
ISSN1569-8041
AutoresAlison M. Schram, Teresa Macarulla, James M. Cleary, Cindy Neuzillet, Dirk Arnold, Kim A. Reiss, Tanios Bekaii‐Saab, Jordi Rodón, Kōichi Goto, Sun Young Rha, M. Duruisseaux, Natasha B. Leighl, Benjamin A. Weinberg, Mohammed Najeeb Al Hallak, Andrew K. Joe, S. Adeyemi, Ernesto Wasserman, K-J. Koeman, Alexander Drilon, Eileen M. O’Reilly,
Tópico(s)HER2/EGFR in Cancer Research
ResumoNRG1 fusions are rare oncogenic drivers of PDAC and other solid tumours. These chimeric proteins bind HER3, leading to HER2/HER3 heterodimerization and oncogenic transformation. Zenocutuzumab (MCLA-128; Zeno) is a bispecific antibody that overcomes HER3 mediated NRG1 signalling in NRG1+ cancer. Zeno is being evaluated in the ongoing pivotal phase II eNRGy study and early access program (EAP). Updated NRG1+ PDAC data are presented.
Referência(s)